Coherus (NASDAQ: CHRS) reprices 3.2M CEO stock options to $1.59

Rhea-AI Filing Summary

Coherus Oncology, Inc. reported that President & CEO Dennis M. Lanfear received multiple stock option grants covering a total of 3,205,000 shares of common stock at an exercise price of $1.59 per share. These new options replace an equal number of older options with exercise prices ranging from $5.44 to $18.33, which were disposed of back to the company.

Stockholders approved this option repricing on May 29, 2026, and the repricing is conditioned on Lanfear remaining in service through May 29, 2027. One block of options vests in 1/48th monthly installments measured from January 5, 2023, while another block is fully vested and exercisable, aligning his compensation structure more closely with the current share price.

Insights

Equity compensation analyst

CEO options are repriced to $1.59, swapping higher-strike grants.

Coherus awarded President & CEO Dennis M. Lanfear stock options on 3,205,000 shares at an exercise price of $1.59. At the same time, an equal number of existing options with exercise prices between $5.44 and $18.33 were returned to the issuer.

The filing describes this as an option repricing approved by stockholders on May 29, 2026, with terms otherwise unchanged. One option block vests in 1/48th monthly installments from January 5, 2023, and another is fully vested, indicating both retention and incentive elements.

The repricing is contingent on Lanfear remaining in service through May 29, 2027. This structure ties potential upside directly to future share performance at the new exercise price, while eliminating out-of-the-money higher-strike awards. The overall economic impact will depend on future stock price and tenure.

Insider Trade Summary

18 transactions reported

Mixed 18 txns

Insider Lanfear Dennis M

Role President & CEO

Type	Security	Shares	Price	Value
Disposition	Stock Option (Right to Buy)	200,000	$0.00	--
Disposition	Stock Option (Right to Buy)	400,000	$0.00	--
Disposition	Stock Option (Right to Buy)	450,000	$0.00	--
Disposition	Stock Option (Right to Buy)	500,000	$0.00	--
Disposition	Stock Option (Right to Buy)	500,000	$0.00	--
Disposition	Stock Option (Right to Buy)	125,000	$0.00	--
Disposition	Stock Option (Right to Buy)	402,500	$0.00	--
Disposition	Stock Option (Right to Buy)	402,500	$0.00	--
Disposition	Stock Option (Right to Buy)	225,000	$0.00	--
Grant/Award	Stock Option (Right to Buy)	200,000	$0.00	--
Grant/Award	Stock Option (Right to Buy)	400,000	$0.00	--
Grant/Award	Stock Option (Right to Buy)	450,000	$0.00	--
Grant/Award	Stock Option (Right to Buy)	500,000	$0.00	--
Grant/Award	Stock Option (Right to Buy)	500,000	$0.00	--
Grant/Award	Stock Option (Right to Buy)	125,000	$0.00	--
Grant/Award	Stock Option (Right to Buy)	402,500	$0.00	--
Grant/Award	Stock Option (Right to Buy)	402,500	$0.00	--
Grant/Award	Stock Option (Right to Buy)	225,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 0 shares (Direct, null)

Footnotes (1)

1. The option is fully vested and exercisable. The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from January 5, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. On May 29, 2026, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. On May 29, 2026, the Issuer's stockholders approved an option repricing at an exercise price of $1.59 per share (the "Repricing") of the stock options held by current employees and other service providers previously priced at or over $5. The Repricing is subject to the Reporting Person remaining in service to the Issuer through May 29, 2027.

Key Figures

Options granted: 3,205,000 options Exercise price (repriced): $1.59/share Options cancelled: 3,205,000 options +5 more

8 metrics

Options granted 3,205,000 options New CEO stock options at $1.59 exercise price

Exercise price (repriced) $1.59/share New option exercise price approved May 29, 2026

Options cancelled 3,205,000 options Equal number of older options returned to issuer

Old strike example $5.44/share One block of disposed options’ prior exercise price

Highest cancelled strike $18.33/share Highest exercise price among disposed options

Repricing approval date May 29, 2026 Stockholders approved option repricing

Service requirement Through May 29, 2027 Repricing subject to continued service

Vesting schedule 1/48th monthly Measured from January 5, 2023

Key Terms

option repricing, exercise price, stock options, Disposition to issuer, +1 more

5 terms

option repricing financial

"On May 29, 2026, the Issuer's stockholders approved an option repricing at an exercise price of $1.59 per share"

exercise price financial

"approved an option repricing at an exercise price of $1.59 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

stock options financial

"Repricing of the stock options held by current employees and other service providers previously priced at or over $5"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

Disposition to issuer financial

"transaction_code_description": "Disposition to issuer""

vesting financial

"shares subject to the option vest and become exercisable as to 1/48th of the total number of shares"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lanfear Dennis M

(Last) (First) (Middle)

C/O COHERUS ONCOLOGY, INC.

333 TWIN DOLPHIN DRIVE, SUITE 600

(Street)

REDWOOD CITY CALIFORNIA 94065

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Coherus Oncology, Inc. [ CHRS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$12.7	05/29/2026		D			200,000	(1)	08/06/2027	Common Stock	200,000	(3)	0	D
Stock Option (Right to Buy)	$10.05	05/29/2026		D			400,000	(1)	02/01/2028	Common Stock	400,000	(3)	0	D
Stock Option (Right to Buy)	$12.37	05/29/2026		D			450,000	(1)	01/11/2029	Common Stock	450,000	(3)	0	D
Stock Option (Right to Buy)	$17.73	05/29/2026		D			500,000	(1)	01/10/2030	Common Stock	500,000	(3)	0	D
Stock Option (Right to Buy)	$18.33	05/29/2026		D			500,000	(1)	01/23/2031	Common Stock	500,000	(3)	0	D
Stock Option (Right to Buy)	$17.6	05/29/2026		D			125,000	(1)	02/01/2031	Common Stock	125,000	(3)	0	D
Stock Option (Right to Buy)	$15.94	05/29/2026		D			402,500	(1)	01/04/2032	Common Stock	402,500	(3)	0	D
Stock Option (Right to Buy)	$10.37	05/29/2026		D			402,500	(2)	01/05/2033	Common Stock	402,500	(3)	0	D
Stock Option (Right to Buy)	$5.44	05/29/2026		D			225,000	(1)	06/13/2033	Common Stock	225,000	(3)	0	D
Stock Option (Right to Buy)	$1.59(4)	05/29/2026		A		200,000		(1)	05/29/2036	Common Stock	200,000	(3)	200,000	D
Stock Option (Right to Buy)	$1.59(4)	05/29/2026		A		400,000		(1)	05/29/2036	Common Stock	400,000	(3)	400,000	D
Stock Option (Right to Buy)	$1.59(4)	05/29/2026		A		450,000		(1)	05/29/2036	Common Stock	450,000	(3)	450,000	D
Stock Option (Right to Buy)	$1.59(4)	05/29/2026		A		500,000		(1)	05/29/2036	Common Stock	500,000	(3)	500,000	D
Stock Option (Right to Buy)	$1.59(4)	05/29/2026		A		500,000		(1)	05/29/2036	Common Stock	500,000	(3)	500,000	D
Stock Option (Right to Buy)	$1.59(4)	05/29/2026		A		125,000		(1)	05/29/2036	Common Stock	125,000	(3)	125,000	D
Stock Option (Right to Buy)	$1.59(4)	05/29/2026		A		402,500		(1)	05/29/2036	Common Stock	402,500	(3)	402,500	D
Stock Option (Right to Buy)	$1.59(4)	05/29/2026		A		402,500		(2)	05/29/2036	Common Stock	402,500	(3)	402,500	D
Stock Option (Right to Buy)	$1.59(4)	05/29/2026		A		225,000		(1)	05/29/2036	Common Stock	225,000	(3)	225,000	D

Explanation of Responses:

1. The option is fully vested and exercisable.

2. The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from January 5, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

3. On May 29, 2026, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged.

4. On May 29, 2026, the Issuer's stockholders approved an option repricing at an exercise price of $1.59 per share (the "Repricing") of the stock options held by current employees and other service providers previously priced at or over $5. The Repricing is subject to the Reporting Person remaining in service to the Issuer through May 29, 2027.

	/s/ Bryan McMichael, as Attorney-in-Fact for Dennis M. Lanfear	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)